Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
62
TYRA Quote, Financials, Valuation and Earnings
Last price:
$33.33
Seasonality move
:
-9.56%
Day range:
$32.01 - $33.72
52-week range:
$6.42 - $35.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
6.34x
Volume:
695.6K
Avg. volume:
781.1K
1-year change:
184.22%
Market cap:
$1.8B
Revenue:
--
EPS (TTM):
-$1.88
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TYRA
Tyra Biosciences, Inc.
|
-- | -$0.53 | -- | -17.55% | $49.29 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.6M | $0.14 | 15.84% | -39.29% | $31.80 |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$12.1M | -$1.95 | 59.92% | -15.51% | $38.88 |
|
BBIO
BridgeBio Pharma, Inc.
|
$149.1M | -$0.62 | 56.6% | -43.21% | $100.05 |
|
NUVL
Nuvalent, Inc.
|
-- | -$1.44 | -- | -23.23% | $143.18 |
|
SYRE
Spyre Therapeutics, Inc.
|
-- | -$0.80 | 315.28% | -9.26% | $58.57 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TYRA
Tyra Biosciences, Inc.
|
$33.31 | $49.29 | $1.8B | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$24.56 | $31.80 | $4.2B | 10.73x | $0.00 | 0% | 3.89x |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$30.23 | $38.88 | $1.8B | 3.91x | $0.00 | 0% | 32.43x |
|
BBIO
BridgeBio Pharma, Inc.
|
$66.48 | $100.05 | $12.9B | -- | $0.00 | 0% | 25.36x |
|
NUVL
Nuvalent, Inc.
|
$101.95 | $143.18 | $7.4B | -- | $0.00 | 0% | -- |
|
SYRE
Spyre Therapeutics, Inc.
|
$43.01 | $58.57 | $3.4B | -- | $0.00 | 0% | 701.12x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TYRA
Tyra Biosciences, Inc.
|
2.07% | 1.209 | 0.79% | 17.31x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 2.900 | 1.15% | 3.40x |
|
AGIO
Agios Pharmaceuticals, Inc.
|
3.26% | 2.234 | 2.53% | 10.52x |
|
BBIO
BridgeBio Pharma, Inc.
|
424.96% | 0.352 | 18.3% | 2.53x |
|
NUVL
Nuvalent, Inc.
|
-- | 0.872 | -- | 10.58x |
|
SYRE
Spyre Therapeutics, Inc.
|
-- | 1.781 | -- | 12.89x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TYRA
Tyra Biosciences, Inc.
|
-$131K | -$32.9M | -34% | -34.65% | -- | -$22.4M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$16.8M | -$121.6M | -29.08% | -30.11% | -608.9% | -$97.3M |
|
BBIO
BridgeBio Pharma, Inc.
|
$145.3M | -$128.4M | -96.35% | -- | -83.3% | -$56.5M |
|
NUVL
Nuvalent, Inc.
|
-- | -$112.7M | -38.24% | -38.24% | -- | -$70.5M |
|
SYRE
Spyre Therapeutics, Inc.
|
-- | -$57.2M | -25.86% | -25.86% | -- | -$44.6M |
Tyra Biosciences, Inc. vs. Competitors
-
Which has Higher Returns TYRA or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Tyra Biosciences, Inc.'s net margin of 96.33%. Tyra Biosciences, Inc.'s return on equity of -34.65% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital TYRATyra Biosciences, Inc.-- -$0.50 $286.4M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About TYRA or ACAD?
Tyra Biosciences, Inc. has a consensus price target of $49.29, signalling upside risk potential of 47.98%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.80 which suggests that it could grow by 29.48%. Given that Tyra Biosciences, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Tyra Biosciences, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TYRATyra Biosciences, Inc.9 0 0 ACADACADIA Pharmaceuticals, Inc.11 5 1 -
Is TYRA or ACAD More Risky?
Tyra Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock TYRA or ACAD?
Tyra Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tyra Biosciences, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TYRA or ACAD?
Tyra Biosciences, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Tyra Biosciences, Inc.'s net income of -$29.9M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Tyra Biosciences, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 10.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tyra Biosciences, Inc. is -- versus 3.89x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TYRATyra Biosciences, Inc.-- -- -- -$29.9M ACADACADIA Pharmaceuticals, Inc.3.89x 10.73x $284M $273.6M
-
Which has Higher Returns TYRA or AGIO?
Agios Pharmaceuticals, Inc. has a net margin of -- compared to Tyra Biosciences, Inc.'s net margin of -541.09%. Tyra Biosciences, Inc.'s return on equity of -34.65% beat Agios Pharmaceuticals, Inc.'s return on equity of -30.11%.
Company Gross Margin Earnings Per Share Invested Capital TYRATyra Biosciences, Inc.-- -$0.50 $286.4M AGIOAgios Pharmaceuticals, Inc.84.25% -$1.85 $1.2B -
What do Analysts Say About TYRA or AGIO?
Tyra Biosciences, Inc. has a consensus price target of $49.29, signalling upside risk potential of 47.98%. On the other hand Agios Pharmaceuticals, Inc. has an analysts' consensus of $38.88 which suggests that it could grow by 28.6%. Given that Tyra Biosciences, Inc. has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe Tyra Biosciences, Inc. is more attractive than Agios Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TYRATyra Biosciences, Inc.9 0 0 AGIOAgios Pharmaceuticals, Inc.7 3 0 -
Is TYRA or AGIO More Risky?
Tyra Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Agios Pharmaceuticals, Inc. has a beta of 0.915, suggesting its less volatile than the S&P 500 by 8.508%.
-
Which is a Better Dividend Stock TYRA or AGIO?
Tyra Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agios Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tyra Biosciences, Inc. pays -- of its earnings as a dividend. Agios Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TYRA or AGIO?
Tyra Biosciences, Inc. quarterly revenues are --, which are smaller than Agios Pharmaceuticals, Inc. quarterly revenues of $20M. Tyra Biosciences, Inc.'s net income of -$29.9M is higher than Agios Pharmaceuticals, Inc.'s net income of -$108M. Notably, Tyra Biosciences, Inc.'s price-to-earnings ratio is -- while Agios Pharmaceuticals, Inc.'s PE ratio is 3.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tyra Biosciences, Inc. is -- versus 32.43x for Agios Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TYRATyra Biosciences, Inc.-- -- -- -$29.9M AGIOAgios Pharmaceuticals, Inc.32.43x 3.91x $20M -$108M
-
Which has Higher Returns TYRA or BBIO?
BridgeBio Pharma, Inc. has a net margin of -- compared to Tyra Biosciences, Inc.'s net margin of -126.24%. Tyra Biosciences, Inc.'s return on equity of -34.65% beat BridgeBio Pharma, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TYRATyra Biosciences, Inc.-- -$0.50 $286.4M BBIOBridgeBio Pharma, Inc.94.27% -$1.00 $652.1M -
What do Analysts Say About TYRA or BBIO?
Tyra Biosciences, Inc. has a consensus price target of $49.29, signalling upside risk potential of 47.98%. On the other hand BridgeBio Pharma, Inc. has an analysts' consensus of $100.05 which suggests that it could grow by 50.49%. Given that BridgeBio Pharma, Inc. has higher upside potential than Tyra Biosciences, Inc., analysts believe BridgeBio Pharma, Inc. is more attractive than Tyra Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TYRATyra Biosciences, Inc.9 0 0 BBIOBridgeBio Pharma, Inc.15 1 0 -
Is TYRA or BBIO More Risky?
Tyra Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BridgeBio Pharma, Inc. has a beta of 1.128, suggesting its more volatile than the S&P 500 by 12.752%.
-
Which is a Better Dividend Stock TYRA or BBIO?
Tyra Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tyra Biosciences, Inc. pays -- of its earnings as a dividend. BridgeBio Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TYRA or BBIO?
Tyra Biosciences, Inc. quarterly revenues are --, which are smaller than BridgeBio Pharma, Inc. quarterly revenues of $154.2M. Tyra Biosciences, Inc.'s net income of -$29.9M is higher than BridgeBio Pharma, Inc.'s net income of -$194.6M. Notably, Tyra Biosciences, Inc.'s price-to-earnings ratio is -- while BridgeBio Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tyra Biosciences, Inc. is -- versus 25.36x for BridgeBio Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TYRATyra Biosciences, Inc.-- -- -- -$29.9M BBIOBridgeBio Pharma, Inc.25.36x -- $154.2M -$194.6M
-
Which has Higher Returns TYRA or NUVL?
Nuvalent, Inc. has a net margin of -- compared to Tyra Biosciences, Inc.'s net margin of --. Tyra Biosciences, Inc.'s return on equity of -34.65% beat Nuvalent, Inc.'s return on equity of -38.24%.
Company Gross Margin Earnings Per Share Invested Capital TYRATyra Biosciences, Inc.-- -$0.50 $286.4M NUVLNuvalent, Inc.-- -$1.70 $845.4M -
What do Analysts Say About TYRA or NUVL?
Tyra Biosciences, Inc. has a consensus price target of $49.29, signalling upside risk potential of 47.98%. On the other hand Nuvalent, Inc. has an analysts' consensus of $143.18 which suggests that it could grow by 40.44%. Given that Tyra Biosciences, Inc. has higher upside potential than Nuvalent, Inc., analysts believe Tyra Biosciences, Inc. is more attractive than Nuvalent, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TYRATyra Biosciences, Inc.9 0 0 NUVLNuvalent, Inc.14 0 0 -
Is TYRA or NUVL More Risky?
Tyra Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nuvalent, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TYRA or NUVL?
Tyra Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuvalent, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tyra Biosciences, Inc. pays -- of its earnings as a dividend. Nuvalent, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TYRA or NUVL?
Tyra Biosciences, Inc. quarterly revenues are --, which are smaller than Nuvalent, Inc. quarterly revenues of --. Tyra Biosciences, Inc.'s net income of -$29.9M is higher than Nuvalent, Inc.'s net income of -$122.4M. Notably, Tyra Biosciences, Inc.'s price-to-earnings ratio is -- while Nuvalent, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tyra Biosciences, Inc. is -- versus -- for Nuvalent, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TYRATyra Biosciences, Inc.-- -- -- -$29.9M NUVLNuvalent, Inc.-- -- -- -$122.4M
-
Which has Higher Returns TYRA or SYRE?
Spyre Therapeutics, Inc. has a net margin of -- compared to Tyra Biosciences, Inc.'s net margin of --. Tyra Biosciences, Inc.'s return on equity of -34.65% beat Spyre Therapeutics, Inc.'s return on equity of -25.86%.
Company Gross Margin Earnings Per Share Invested Capital TYRATyra Biosciences, Inc.-- -$0.50 $286.4M SYRESpyre Therapeutics, Inc.-- -$0.69 $715.2M -
What do Analysts Say About TYRA or SYRE?
Tyra Biosciences, Inc. has a consensus price target of $49.29, signalling upside risk potential of 47.98%. On the other hand Spyre Therapeutics, Inc. has an analysts' consensus of $58.57 which suggests that it could grow by 36.18%. Given that Tyra Biosciences, Inc. has higher upside potential than Spyre Therapeutics, Inc., analysts believe Tyra Biosciences, Inc. is more attractive than Spyre Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TYRATyra Biosciences, Inc.9 0 0 SYRESpyre Therapeutics, Inc.16 0 0 -
Is TYRA or SYRE More Risky?
Tyra Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Spyre Therapeutics, Inc. has a beta of 3.152, suggesting its more volatile than the S&P 500 by 215.196%.
-
Which is a Better Dividend Stock TYRA or SYRE?
Tyra Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spyre Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tyra Biosciences, Inc. pays -- of its earnings as a dividend. Spyre Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TYRA or SYRE?
Tyra Biosciences, Inc. quarterly revenues are --, which are smaller than Spyre Therapeutics, Inc. quarterly revenues of --. Tyra Biosciences, Inc.'s net income of -$29.9M is higher than Spyre Therapeutics, Inc.'s net income of -$51.8M. Notably, Tyra Biosciences, Inc.'s price-to-earnings ratio is -- while Spyre Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tyra Biosciences, Inc. is -- versus 701.12x for Spyre Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TYRATyra Biosciences, Inc.-- -- -- -$29.9M SYRESpyre Therapeutics, Inc.701.12x -- -- -$51.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Feb 28
Applied Optoelectronics, Inc. [AAOI] is up 56.96% over the past day.
Buy
90
BNAI alert for Feb 28
Brand Engagement Network, Inc. [BNAI] is up 36.02% over the past day.
Sell
36
WLDN alert for Feb 28
Willdan Group, Inc. [WLDN] is down 25.56% over the past day.
